Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Like any other aspect of financial planning, without a strategy, credit card perks may go unclaimed. Here’s what consumers ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

Some doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures.

Healthcare inflation outpaces CPI due to provider shortages. Find out why income investing ensures steady returns despite ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...